Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP Chief R&D | March 04, 2026 | March 06, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,693 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 106 · Balance 23,300 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 23,198 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 22,983 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 22,694 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 22,344 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 21,577 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 21,305 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 21,097 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 654 · Balance 20,443 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 740 · Balance 19,703 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 510 · Balance 19,193 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 500 · Balance 18,693 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 431 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 431 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 250 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 250 F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 500 | $326.08 | $163,040.00 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,693 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 510 | $324.59 | $165,540.90 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,193 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 740 | $323.55 | $239,427.00 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,703 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 654 | $322.33 | $210,803.82 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,443 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 208 | $325.67 | $67,739.36 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,097 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 272 | $324.88 | $88,367.36 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,305 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 767 | $323.84 | $248,385.28 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,577 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 350 | $323.01 | $113,053.50 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,344 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 289 | $321.82 | $93,005.98 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,694 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 215 | $320.81 | $68,974.15 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,983 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 102 | $320.01 | $32,641.02 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,198 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 106 | $319.03 | $33,817.18 |
DisclosureSEC source: 0001735276-26-000063 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,300 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 463 | $321.50 | $148,854.50 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,406 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.30 to $321.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 640 | $320.48 | $205,107.20 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,869 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.97 to $320.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 317 | $319.06 | $101,142.02 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,509 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.71 to $319.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 355 | $316.74 | $112,442.70 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,826 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.45 to $317.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 10,480 | $0.00 Strike: $325.07 | $0.00 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · derivative · entry 18 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,480 Underlying: Common Stock · 10,480 shares Expires 2036-03-02 F20 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 42 | $332.64 | $13,970.88 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,181 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 101 | $331.93 | $33,524.93 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,223 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 87 | $330.85 | $28,783.95 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,324 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 182 | $329.71 | $60,007.22 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,411 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 107 | $328.71 | $35,171.97 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,593 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 353 | $327.67 | $115,667.51 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,700 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 421 | $326.81 | $137,587.01 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,053 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 277 | $325.63 | $90,199.51 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,474 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 97 | $324.65 | $31,491.05 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,751 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 50 | $323.62 | $16,181.00 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,848 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000052 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,898 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · derivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. F9 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F10 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 140 | $334.39 | $46,814.60 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,129 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 942 | $332.48 | $313,196.16 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,269 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.11 to $333.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,159 | $331.49 | $384,196.91 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,211 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.09 to $332.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,259 | $330.73 | $747,119.07 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.08 to $331.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 127 | $328.92 | $41,772.84 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,629 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.90 to $329.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000038 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 00:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,242 | $310.08 | $695,201.15 |
DisclosureSEC source: 0001735276-26-000029 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,848 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000029 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,090 F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15 | $377.82 | $5,667.30 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 22 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,511 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 19 | $375.65 | $7,137.35 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 21 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,526 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14 | $374.44 | $5,242.16 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 20 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,545 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F21 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3 | $372.46 | $1,117.38 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 19 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,559 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F20 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 18 | $370.87 | $6,675.66 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 18 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,562 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F19 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 40 | $369.48 | $14,779.20 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 17 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,580 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F18 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 92 | $368.62 | $33,913.04 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 16 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,620 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 41 | $367.40 | $15,063.40 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,712 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 50 | $366.41 | $18,320.50 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,753 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 220 | $365.56 | $80,423.20 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,803 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 199 | $364.83 | $72,601.17 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,023 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $363.55 | $17,086.85 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,222 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $362.38 | $26,453.74 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,269 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.